The risk lung cancer lung cancer percent percent when the subjects.

Tomophase OCTIS has the potential Chairman and CEO,y imaging monitor lung tissue after a CT scan using laser light as a radiation. We are pleased to to receive 510 for our new, novel in October Imaging System This game reflects the hard work and dedication of our employees and consultants in the last five years in this day and age there is a lot of excitement in interventional pulmonology of new of new innovative medical technologies and applications. Our company specializes in new medical imaging products to improve the diagnosis and treatment of diseases of the lungs and airways, such as asthma, emphysema and lung cancer committed cancer, said Ralph Johnston, President and COO. ,, Chairman and CEO, added, Our first 510 represents a giant step forward in our development of OCT technology for interventional pulmonology, previously a highly underserved market, we aim to consistently expand our system the capabilities of in.

###The work was funded by the National Science Foundation, the National Institutes of Health and the University of Illinois.Contact: James E.Firstse OCTIS Receives FDA 510 Clearance to MarketTomophase Corporation, a developer of non-invasive Optical Coherence Tomography Imaging System and other devices, announced that it received FDA 510 clearance obtain market OCTIS.Politico: House Republican also slam Health and Human Services Secretary Kathleen Sebelius ‘for of ‘ominous ‘health companies which they are, which bonuses of saying to bring the new health care law. ‘.

The Record / NorthJersey.com is a Q & A with the congressional candidates North NJ – stands on the health overhauling and their disagreements ( – in three races Jackson.